Sativa Wellness Group Inc (AQSE:SWEL) said it has witnessed record sales in December.
In a brief update, the chief executive of the cannabis and cannabidiol (CBD) wellness firm Henry Lees-Buckley said 2020 had been a “transformational year for the company” and that the company’s integrated supply chain allowed them to control quality and costs.
READ: Sativa Wellness highlights regulatory progress for cannabis and CBD in the EU, US and the UN
“Producing a traceable high-quality product has never been more important than today as we approach the UK FSA Novel Food validation deadline at the end of March. Sativa is well prepared for this process and embraces a market with high quality, compliant products”, the CEO said.
Looking ahead to 2021, Lees-Buckley said the firm is focused on continuing to drive sales in the UK and extending its reach into Europe.
“We already have a strong presence in Europe with our extraction and production plant, and we are now extending our capabilities to sell and distribute our products in European markets”, he added.